#USA #New Orleans #Type 1 Diabetes #GLP-1/GIP #Acmopatide

Dual GLP-1/GIP Receptor Agonist: A Breakthrough for Type 1 Diabetes

In a significant advancement, a recent study has shown that acmopatide (CT-868), a dual glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptor agonist, can effectively manage blood glucose levels and support weight loss in individuals with Type 1 diabetes. The findings, which were shared during a symposium at the 2026 American Diabetes Association's Scientific Sessions in New Orleans, highlight the potential benefits of this once-daily injection treatment.

The Importance of the Study

Approximately 1.2 million people in the United States are affected by Type 1 diabetes, a condition that requires daily insulin administration to manage blood glucose levels. However, many individuals also struggle with weight gain, resulting in a heightened risk of complications such as heart disease and kidney failure. This underscores the urgent need for new non-insulin therapies that can assist in glucose regulation while also promoting weight loss.

Study Design and Implementation

The Phase 2 clinical trial recruited 111 adults classified as overweight or obese, with a Body Mass Index (BMI) of 27 kg/m² or higher. Participants were randomly assigned to receive different doses of acmopatide (1.8 mg, 4.1 mg, and 6.6 mg) or a placebo. The primary goal of the study was to measure the changes in A1C levels, a crucial indicator of long-term glucose control, over a 16-week treatment period. Secondary objectives included monitoring body weight, insulin dosages, and real-time glucose readings via continuous glucose monitors (CGM).

Findings and Results

The results were promising. Patients receiving the 4.1 mg dose had their A1C levels drop by an average of 0.34%, with 56% of participants reaching the target A1C level of below 7%. Furthermore, treatment with acmopatide resulted in weight loss averaging around 7% and a corresponding reduction in daily insulin requirements by up to 15%, compared to those on placebo, demonstrating its effectiveness as a weight management aid alongside blood sugar control. The medication was generally well tolerated, with no significant safety concerns raised.

The Implications for Diabetes Management

Dr. Klara Klein, the lead author of the study, noted, "Despite significant advancements in diabetes care, individuals with Type 1 diabetes still have limited treatment options beyond insulin therapy. The results from our study showcase the potential for acmopatide to be the first incretin-based therapy specifically designed for Type 1 diabetes patients, helping them achieve better glycemic control and support weight management. This could significantly alleviate the burden of complications associated with Type 1 diabetes."

Upcoming Research Directions

While these results are encouraging, further research will be necessary to establish the long-term effects of dual receptor agonists on Type 1 diabetes management. The dual actions of GIP and GLP-1 may open up new avenues for treatment that not only help patients manage their diabetes more effectively but also tackle the accompanying issues of weight gain commonly seen with insulin use.

Conclusion

The development of acmopatide presents a promising step forward in the treatment of Type 1 diabetes, offering hope for improved management of blood glucose levels and weight reduction. The ongoing research and findings from the ADA's Scientific Sessions suggest that new therapies could transform care for those living with this chronic condition, making daily life easier and healthier for millions.

This study marks a milestone in diabetes treatment, potentially changing the landscape of care for many who manage Type 1 diabetes, paving the way for further innovations in therapeutic interventions.